Post-Hoc• May 28, 2025• 31:20

Post-Hoc: Is biotech sentiment as bad as it seems?

From Post-Hoc

Drew Armstrong

Executive Summary

The biotech industry is experiencing its most negative sentiment in nearly a decade, as revealed by the Endpoints 100 survey of executives.
A prolonged, three-year market downturn has created a severe capital crunch, with a record 58% of executives rating VC investment flow as "poor" and 180 public companies trading below cash.
Significant uncertainty surrounds the new political administration's impact on the FDA, with 75% of executives expecting the agency's reorganization to be harmful to the industry.
In response to the harsh environment, company boards are shifting strategy, becoming more willing to quickly shut down struggling companies rather than attempting multiple turnarounds.

12 quotes

Concerns Raised

Prolonged capital market downturn with no clear bottom.
Political interference and regulatory instability at the FDA.
Difficulty in raising capital, especially for early-stage companies.
Continuing R&D decoupling from China, adding complexity and cost.

Opportunities Identified

Low valuations create M&A opportunities for well-capitalized buyers.
Capital concentration may benefit a select few companies with best-in-class science and management.

Key Themes

Unprecedented Industry Pessimism

The latest Endpoints 100 survey reveals the most negative sentiment among biotech and pharma executives in its history. This 'winter of discontent' is driven by a market downturn that has now lasted three years, far longer than anticipated, with no clear end in sight.

This pervasive bleak outlook directly impacts strategic decisions, suppressing hiring, discouraging investment, and creating a risk-averse environment that can stifle innovation.

Capital Scarcity and Investor Caution

Access to capital is a primary concern, with a record number of executives rating VC funding as poor and zero rating it as excellent. Investors are concentrating capital on a smaller number of portfolio companies, leading to a drop in mega-rounds and making it exceptionally difficult for early-stage or struggling companies to raise funds.

This funding drought is forcing companies to make difficult choices, including layoffs and shutdowns, and has led to a large number of 'zombie' biotechs trading for less than their cash on hand.

Political and Regulatory Uncertainty

The new political administration has introduced significant anxiety regarding the future of the FDA and science-based policy. Executives overwhelmingly disapprove of leadership changes at CIBER and anticipate that the FDA's reorganization will have a harmful effect on the industry, potentially causing drug approval delays.

Regulatory stability is the bedrock of biopharma investment and long-term R&D. The current uncertainty creates a volatile environment that can delay the delivery of new medicines to patients and deter investment in the sector.

Shifting Corporate Survival Strategies

The prolonged downturn is forcing a change in mindset from the industry's traditional 'nine lives' approach. Boards are now making faster, more decisive calls to wind down operations when strategic alternatives fail, as exemplified by Ikena Oncology's rapid shutdown.

This signals a new era of capital discipline where investors and boards are less patient with underperforming assets, leading to a faster culling of the industry's weakest companies.

Get started free

Topics

Biotech Industry Pharmaceuticals Venture Capital Endpoints 100 Survey Market Sentiment Biotech Downturn Capital Markets FDA Regulatory Policy M&A Corporate Strategy Geopolitics US-China Relations Drug Development Biotech Investing

Processed Apr 20, 2026 yt-dlp + mlx-whisper + Gemini